Article
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
Cell reports - 17 May 2016
Howell Katie A, Qiu Xiangguo, Brannan Jennifer M, Bryan Christopher, Davidson Edgar, Holtsberg Frederick W, Wec Anna Z, Shulenin Sergey, Biggins Julia E, Douglas Robin, Enterlein Sven G, Turner Hannah L, Pallesen Jesper, Murin Charles D, He Shihua, Kroeker Andrea, Vu Hong, Herbert Andrew S, Fusco Marnie L, Nyakatura Elisabeth K, Lai Jonathan R, Keck Zhen-Yong, Foung Steven K H, Saphire Erica Ollmann, Zeitlin Larry, Ward Andrew B, Chandran Kartik, Doranz Benjamin J, Kobinger Gary P, Dye John M, Aman M Javad
Abstract excerpt
Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.